卡瑞利珠单抗联合化疗治疗晚期NSCLC疗效及其对血清SCC-Ag、TIMP-1、D-二聚体、miR-206水平的影响

目的探讨卡瑞利珠单抗联合化疗治疗晚期非小细胞肺癌(NSCLC)的疗效及其对血清鳞状细胞癌抗原(SCC-Ag)、基质金属蛋白酶组织抑制剂-1(TIMP-1)、D-二聚体(D-D)、微小核糖核酸-206(miR-206)水平的影响。方法选取2022年4月—2023年10月保定市第二中心医院肿瘤科收治的晚期NSCLC患者110例为研究对象,按照随机数字表法分为对照组55例和观察组55例。对照组采用一线化疗方案,观察组在对照组基础上加用卡瑞利珠单抗治疗,21 d为1个周期,共治疗4~6个周期。采用酶联免疫吸附法(ELISA)检测血清SCC-Ag、TIMP-1、D-D水平,实时荧光定量PCR(qPCR)检测miR-206表达水平。比较2组患者临床疗效、治疗前后血清学指标、T淋巴细胞亚群水平及不良反应。结果观察组临床总有效率高于对照组(78.18%vs.60.00%,χ^(2)/P=4.257/0.039);与治疗前比较,治疗4~6个周期后2组血清SCC-Ag、TIMP-1、D-D水平均降低,miR-206表达升高,且观察组各指标降低/升高幅度大于对照组(t/P=38.360/<0.001、4.156/<0.001、9.567/<0.001、4.857/<0.001);与治疗前比较,治疗4~6个周期后2组CD4^(+)T淋巴细胞、CD4^(+)/CD8^(+)升高,CD8^(+)T淋巴细胞降低,且观察组各指标降低/升高幅度大于对照组(t/P=6.241/<0.001、6.879/<0.001、5.631/<0.001);治疗期间,观察组不良反应总发生率低于对照组(5.45%vs.21.82%,χ^(2)/P=6.253/0.012)。结论卡瑞利珠单抗联合化疗治疗晚期NSCLC患者的疗效确切,可有效改善机体免疫功能,降低血清SCC-Ag、TIMP-1、D-二聚体水平,提高miR-206水平。

Modulation of Matrix Metalloproteinase and TIMP-1 Expression by TGF-β_1 in Cultured Human RPE Cells

In order to investigate the effects of TGF-β1 on the expression of MMP-2, -9 and TIMP- 1 in human retinal pigment epithelial （RPE） cells, the third-sixth passage cultured RPE cells were treated with TGF-β1 at different concentrations （0.01, 0. 1, 1.0, 10 ng/mL）, the expression of MMP-2, -9 and TIMP-1 mRNA was detected by semi-qudntitative RT-PCR assays. MMP-2, -9 and TIMP-1 mRNA were expressed in the cultured RPE cells. The values of MMP-2/β-actin in the cells treated with 0.1, 1.0, 10 ng/mL TGF-β1 were 1.04±0.04, 1.07±0.02 and 1.11±0.03, respectively, significantly higher than in the control group （0.96±0.03, P〈0. 05-0.01）. The expression of MMP-2 mRNA could be up-regulated by TGF-β, , in a dose-dependent manner. The expression of MMP-9 mRNA in the cultured RPE cells was slightly up-regulated by various TGF-β1 concentrations treatment. The values of TIMP-1/β-actin in the cells treated with 0.01 and 0.1 ng/ mL TGF-β1 were 0.85 ±0.01 and 0.97 ± 0.02 respectively, significantly lower than in the control group （1.07±0.04, P〈0.01）, indicating that the expression of TIMP-1 mRNA was down-regulated by TGF-β1 at low concentrations. But along with the increase of TGF-β1 concentrations （1.0 and 10 ng/mL）, the expression of TIMP-1 mRNA was slightly up-regulated, not significantly different from that in the control group （P〉0.05）. It was concluded that TGF-β1 might play an important role in the up-regulation of the expression of MMP-2 in RPE cells and result in a directional shift in the balance between MMP and TIMP. This may be facilitated for RPE cells to migrate in the pathogenesis of vitreoretinopathy.

Imbalance of matrix metalloproteinase-9 and matrix metalloproteinase tissue inhibitor-1 may contribute to hemorrhage in cerebellar arteriovenous malformations

In this study, we determined the expression levels of matrix metalloproteinase-2 and -9 and matrix metalloproteinase tissue inhibitor-1 and -2 in brain tissues and blood plasma of patients undergoing surgery for cerebellar arteriovenous malformations or primary epilepsy （control group）. Immunohistochemistry and enzyme-linked immunosorbent assay revealed that the expression of matrix metalloproteinase-9 and matrix metalloproteinase tissue inhibitor-1 was significantly higher in patients with cerebellar arteriovenous malformations than in patients with primary epilepsy. The ratio of matrix metalloproteinase-9 to matrix metalloproteinase tissue inhibitor-1 was significantly higher in patients with hemorrhagic cerebellar arteriovenous malformations compared with those with non-hemorrhagic malformations. Matrix metalloproteinase-2 and matrix metalloproteinase tissue inhibitor-2 levels were not significantly changed. These findings indicate that an imbalance of matrix metalloproteinase-9 and matrix metalloproteinase tissue inhibitor-I, resulting in a relative overabundance of matrix metalloproteinase-9, might be the underlying mechanism of hemorrhage of cerebellar arteriovenous malformations.

Correlation of matrix metalloproteinase－2, －9, tissue inhibitor－1 of matrix metalloproteinase and CD44 variant 6 in head and neck cancer metastasis

This study aimed to explore the molecular mechanism in tumor invasion and metastasis. The expression of matrix metalloproteinase 2, 9 (MMP 2, MMP 9), tissue inhibitor 1 of matrix metalloproteinase (TIMP 1), cell adhesion molecule 44 variant 6 (CD44v6), HER2/neu and p53 was investigated in 154 patients with head and neck squamous cell carcinoma (SCC) by ABC and ImmunoMax immunohistochemical method. Their clinical relevance and correlation were analysed. The expression of MMP 2, MMP 9, TIMP 1, CD44v6, HER2/neu and p53 was found in cancer cells in 87.01%, 85.71%, 68.18%, 98.05%, 55.19% and 50.65% cases respectively. Linear regression and correlation analysis revealed that there was close positive relationship ( P <0.05) between the expression of MMP 2 and MMP 9, TIMP 1 and CD44v6, HER2/neu and MMP 9, MMP 2 and p53. Up regulation of MMP 2 was accompanied by advanced T stage ( P <0.01) . There was also a trend of MMP 2 expression being related with tumor metastasis. Increased expression of HER2/neu was found in patients with tumor recurrence( P <0.05). The expression of TIMP 1 was higher in laryngeal cancer than that in pharyngeal cancer, and higher in keratinizing and non keratinizing SCC than that in basaloid SCC( P <0.05). These findings suggested that MMP 2 and MMP 9, HER2/neu and MMP 9, MMP 2 and p53 had a coordinate function in aggression of tumor; that MMP 2 had a more important function than MMP 9 in tumor invasion and metastasis; and that HER2/neu might serve as a biomarker for poor prognosis in HNSCC.

Local inhibition of matrix metalloproteinases reduced M2 macrophage activity and impeded recovery in spinal cord transected rats after treatment with fibroblast growth factor-1 and nerve grafts

Alternatively activated macrophages （M2 macrophages） promote central nervous system regeneration. Our previous study demonstrated that treatment with peripheral nerve grafts and fibroblast growth factor-1 recruited more M2 macrophages and improved partial functional recovery in spinal cord transected rats. The migration of macrophages is matrix metalloproteinase （MMP） dependent. We used a general inhibitor of MMPs to influence macrophage migration, and we examined the migration of macrophage populations and changes in spinal function. Rat spinal cords were completely transected at Ts, and 5 mm of spinal cord was removed （group T）. In group R, spinal cord-transected rats received treatment with fibroblast grow th factor- 1 and peripheral nerve grafts. In group RG, rats received the same treatment as group R with the addition of 200 μM GM6001 （an MMP inhibitor） to the fibrin mix. We found that MMP-9, but not MMP- 2, was upregulated in the graft area of rats in group R. Local application of the MMP inhibitor resulted in a reduction in the ratio of arginase-1 （M2 macrophage subset）/inducible nitric oxide synthase-postive cells. When the MMP inhibitor was applied at 8 weeks postoperation, the partial functional recovery observed in group R was lost. This effect was accompanied by a decrease in brain-derived neurotrophic factor levels in the nerve graft. These results suggested that the arginase-1 positive population in spinal cord transected rats is a migratory cell population rather than the phenotypic conversion of early iNOS^＋ cells and that the migration of the arginase-1^＋ population could be regulated locally. Simultaneous application of MMP in- hibitors or promotion of MMP activity for spinal cord injury needs to be considered if the coadministered treatment involves M2 recruitment.

Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in early focal cerebral infarction following urokinase thrombolysis in rats

Activity of matrix metalloproteinase-9 increases following cerebral ischemia/reperfusion, and is associated with cerebral microvascular permeability, blood-brain barrier destruction, inflammatory cell infiltration and brain edema. Matrix metalloproteinase-9 also likely participates in thrombolysis. A rat model of middle cerebral artery infarction was established by injecting autologous blood clots into the internal carotid artery. At 3 hours following model induction, urokinase was injected into the caudal vein. Decreased neurological severity score, reduced infarct volume, and increased expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 were observed in the cerebral cortex 24 hours after urokinase thrombolysis. These results suggest that urokinase can suppress damage in the acute-early stage of cerebral infarction.

乳腺癌组织中TIMP-3及DNMT1的表达与患者预后的相关性

目的:分析研究乳腺癌患者中基质金属蛋白酶组织抑制因子3(TIMP-3)及DNA甲基转移酶1(DNMT1)的表达水平与患者临床预后的相关性。方法:收集58例临床资料完整的乳腺癌手术切除标本,采用免疫组化SP法检测癌组织及相应癌旁组织中TIMP-3、DNMT1、ER、PR、HER-2、p53、Ki-67的表达,将TIMP-3、DNMT1表达水平与临床病理参数及随访生存状况进行相关性分析,所有入组患者均进行随访5年以上。结果:我们发现,在乳腺癌组织中,TIMP-3呈低表达,DNMT1呈高表达,TIMP-3及DNMT1的表达呈负相关;TIMP-3表达水平与Ki-67呈负相关,DNMT1表达水平与Ki-67呈正相关,与其他临床病理参数未见相关性。Cox风险比例模型分析显示只有临床分期和DNMT1表达水平是影响总生存期(OS)和无病生存期(DFS)的独立风险因素。TIMP-3低表达组的5年OS和DFS均显著低于高表达组,DNMT1高表达组的5年OS和DFS均显著低于低表达组。结论:研究表明乳腺癌中TIMP-3及DNMT1表达水平与肿瘤细胞恶性表型及患者生存时间有关,可能成为判断乳腺癌预后的一项重要指标,并作为治疗计划制定的依据。

血清TLR4、TIMP-1水平与小儿热性惊厥临床特征的关系及对继发癫痫的预测价值

目的分析血清Toll样受体4(TLR4)、基质金属蛋白酶组织抑制剂(TIMP)-1水平与小儿热性惊厥(FC)临床特征的关系及对FC继发癫痫的预测价值。方法选取2019年1月至2022年6月320例FC患儿作为研究组,另选取同期发热无惊厥儿童150例作为发热组,体检健康儿童150例作为对照组。根据FC患儿是否继发癫痫分为癫痫组和无癫痫组。采用酶联免疫吸附试验检测血清TLR4、TIMP-1水平,采用Pearson相关分析TLR4、TIMP-1水平及与临床指标间的相关性。采用受试者工作特征(ROC)曲线分析血清TLR4、TIMP-1预测FC继发癫痫的价值。采用Logistic回归分析FC患儿继发癫痫的影响因素。结果FC患儿、发热无惊厥儿童、体检健康儿童血清TLR4、TIMP-1水平依次降低,且两两比较,差异均有统计学意义(P<0.05)。研究组与发热组围生期异常发生情况、肿瘤坏死因子α(TNF-α)、C-反应蛋白(CRP)、白细胞介素-1β(IL-1β)水平和振幅整合脑电图(AEEG)评分比较,差异均有统计学意义(P<0.05)。癫痫组患儿血清TLR4、TIMP-1水平明显高于无癫痫组(P<0.05)。癫痫组和无癫痫组患儿首次惊厥次数、惊厥持续时间、首次惊厥前发热时间、围生期异常发生情况、TNF-α、CRP、IL-1β水平和AEEG评分比较,差异均有统计学意义(P<0.05)。血清TLR4水平与TIMP-1呈正相关(P<0.05);血清TLR4、TIMP-1水平与TNF-α、CRP、IL-1β呈正相关(P<0.05),与AEEG评分呈负相关(P<0.05)。TLR4、TIMP-1联合预测FC患儿继发癫痫的曲线下面积(AUC)明显高于单项检测的AUC(Z_(TLR4-联合)=3.016,P=0.003;Z_(TIMP-1-联合)=2.232,P=0.026)。Logistic回归分析结果表明,TLR4、TIMP-1、TNF-α、CRP、IL-1β水平升高,AEEG评分降低均为FC继发癫痫的危险因素(P<0.05)。结论血清TLR4、TIMP-1与FC患儿临床特征密切相关,TLR4、TIMP-1可能是FC继发癫痫的影响因素。

多西他赛联合PD-1抑制剂对晚期非小细胞肺癌预后及血清MMP-9、TIMP-1水平的影响

目的探讨多西他赛联合程序性死亡受体1(PD-1)抑制剂对晚期非小细胞肺癌(NSCLC)预后及血清基质金属蛋白酶-9(MMP-9)、基质金属蛋白酶组织抑制剂-1(TIMP-1)水平的影响。方法将90例晚期NSCLC患者随机分为研究组和对照组,每组45例。对照组给予多西他赛和顺铂治疗,研究组在对照组治疗基础上给予PD-1治疗,3周为1个治疗周期,共治疗6个周期。比较2组治疗后客观缓解率(ORR)、疾病控制率(DCR)、无进展生存期(PFS)、总生存期(OS),观察2组治疗期间不良反应发生情况及治疗前后血清MMP-9、TIMP-1水平的变化。结果研究组治疗后DCR、PFS、OS显著高于对照组(P<0.05);治疗期间2组不良反应发生率比较差异无统计学意义(P>0.05);2组治疗后血清MMP-9、TIMP-1水平较治疗前显著降低(P<0.05),且研究组降低较对照组更为显著(P<0.05)。结论多西他赛联合PD-1抑制剂对晚期NSCLC具有较好的疗效和预后,能够降低血清MMP-9、TIMP-1水平,降低肺癌细胞侵袭转移的能力,安全性良好。

血清NF-κB、TIMP-1、IL-8与儿童幽门螺杆菌感染相关性胃炎的关系

目的分析血清核因子-κB(NF-κB)、基质金属蛋白酶抑制因子-1(TIMP-1)、白细胞介素-8(IL-8)与儿童幽门螺杆菌(H.pylori)感染相关性胃炎的关系。方法选取2021年7月至2023年7月就诊的60例H.pylori感染相关性胃炎患儿设为观察组,另选取同期体检中心的60例健康体检儿童设为健康组,检测、比较2组血清NF-κB、TIMP-1、IL-8水平,比较观察组患者不同炎性活动度组血清NF-κB、TIMP-1、IL-8水平,比较观察组患者治疗前后血清NF-κB、TIMP-1、IL-8水平,绘制受试者工作曲线(ROC),分析血清NF-κB、TIMP-1、IL-8对H.pylori感染相关性胃炎的诊断效能。结果观察组血清NF-κB、TIMP-1、IL-8水平均高于健康组(P<0.05)。重度组血清NF-κB、TIMP-1、IL-8水平均高于中度组、轻度组(P<0.05),中度组血清NF-κB、TIMP-1、IL-8水平均高于轻度组(P<0.05)。治疗后血清NF-κB、TIMP-1、IL-8水平低于治疗前(P<0.05)。血清NF-κB、TIMP-1、IL-8联合检测诊断H.pylori感染相关性胃炎的AUC是0.904,95%CI可信区间是0.856~0.951,联合检测的灵敏度(94.82%)、特异度(90.13%)均高于单一检测(73.82%、71.62%)、(72.26%、68.18%)、(70.18%、64.74%),差异有统计学意义(P<0.05)。结论H.pylori感染相关性胃炎患儿血清NF-κB、TIMP-1、IL-8呈异常高表达,血清NF-κB、TIMP-1、IL-8表达量与炎性活动度及疗效存在密切联系,联合检测可提高对H.pylori感染相关性胃炎的诊断效能,值得借鉴。

Macrophage-derived matrix metalloproteinase-1 enhances aortic aneurysm formation in transgenic rabbits

Increased expression of matrix metalloproteinase-1(MMP-1)has been observed in the lesions of atherosclerosis and aneurysms;however,it is not fully understood whether macrophage-derived MMP-1 affects these diseases.To investigate whether macrophage-derived MMP-1 participates in the development of vascular diseases,we generated transgenic(Tg)rabbits expressing human MMP-1 in the monocyte/macrophage lineage under the control of the human scavenger receptor enhancer/promoter.Tg rabbits exhibited no visible abnormalities throughout their bodies.Western blotting analysis revealed that the amount of MMP-1 proteins in the conditioned media secreted from peritoneal macrophages of Tg rabbits was up to 3-fold higher than that in non-Tg rabbits.For the first experiment,Tg and non-Tg rabbits were fed a cholesterol diet for 16 weeks,and aortic and coronary atherosclerosis were evaluated.The gross lesion area of aortic atherosclerosis in Tg rabbits was not significantly different from that in non-Tg rabbits,but Tg rabbits had marked destruction of the medial elastic lamina of the aortic lesions on microscopic examination.For the second experiment,we generated aortic aneurysms by incubating with elastase.Compared with non-Tg rabbits,Tg rabbits exhibited a significantly greater aortic dilation.Increased macrophage-derived MMP-1 led to increased medial destruction in both aortic atherosclerosis and aneurysms.These results demonstrate that MMP-1 plays a different role in the pathogenesis of atherosclerosis and aneurysms.

Serum Matrix Metalloproteinase 3 and Tissue Inhibitor Metalloproteinase 1 in Vascular Dementia: A Comparative Study

Aim: To compare serum level of matrix metalloproteinase 3 (MMP3) and tissue inhibitor metallo-proteinase 1 (TIMP1) in vascular dementia patients and healthy control subjects. Methods: A case control study was carried out in Ain Shams University hospital, Cairo, Egypt. 32 cases with vascular dementia were collected and classified into 2 subgroups;vascular dementia of multiinfarct type (VDMI) 14 patients, and vascular dementia of subcortical type (VDSC) 18 subjects. 23 cases with normal cognitive functions were collected as control group. Cases were subjected to comprehensive geriatric assessment, neurological examination, neuropsychological testing and brain CT scan. Blood sample was collected to analyze serum level of matrix metalloproteinase 3 (MMP3) and tissue inhibitor metalloproteinase 1 (TIMP1). Results: Mean serum level of TIMP1 (20.85 × 103 picogram/ml) was significantly lower than mean serum level of TIMP1 in control group (27.69 × 103 picogram/ml) (p = 0.018). The same finding was also evident when comparing VDMI subgroup mean serum TIMP1 (18.71 × 103 pc/ml) to control group (p = 0.025). There was no significant difference between mean serum MMP3 levels in cases group (mean = 67.39 × 103) as compared to control group (mean = 61.65 × 103 pc/ml) (p = 0.519). Conclusion: Patients with VD particularly VDMI has lower serum level of TIMP1 as compared to control group.

Human ciliary muscle cell responses to kinins:Activation of ERK1/2 and pro-matrix metalloproteinases secretion

AIM To study activation of extracellular signal-regulated kinase-1/2(ERK1/2) and pro-matrix metalloproteinases(pro-MMPs) secretion from isolated primary human ciliary muscle(h-CM) cells in response to bradykinin(BK) and other agonists. METHODS Serum-starved h-CM cells were challenged with vehicle, BK agonists or antagonists. Cell lysates were evaluated for phosphorylated ERK1/2 using homogeneous timeresolved fluorescence technology based on a sandwich immunoassay. Rabbit polyclonal anti-pro-MMP antibodies were used to measure pro-MMPs using immunoblot analysis.RESULTS A 10 min incubation time using 5 × 104 h-CM cells/well was optimum condition for studying stimulation of ERK1/2 phosphorylation. BK(100 nmol/L) caused a 1.86 ± 0.26 fold(n = 3) increase in ERK1/2 phosphorylation above baseline. BK analogs, Met-Lys-BK and RMP-7(100 nmol/L), also stimulated ERK1/2 phosphorylation by 1.57 ± 0.04 and 1.55 ± 0.09 fold, respectively. However, DesArg9-Bradykinin, a B1 receptor-selective agonist(0.1-1 μmol/L), was essentially inactive. HOE-140 or WIN-64338(B2-antagonists) appreciably blocked phosphorylation of ERK1/2 induced by various BK agonists. Pre-treatmentof cells with a prostaglandin(PG) synthase inhibitor(bromfenac; 1 μmol/L) failed to alter kinin-induced ERK1/2 activation. BK and a non-peptide BK agonist(FR-190997)(10 nmol/L-1 μmol/L) also enhanced pro-MMPs secretion(pro-MMP-1 > pro-MMP-3 > pro-MMP-2; 1.45-1.75-fold over baseline) from h-CM cells. CONCLUSION These collective data suggest that B2 kinin receptors initiate signaling in h-CM cells by a relatively rapid mechanism(within minutes) involving ERK1/2 activation which in turn regulates MMPs production(within hours). The latter process does not involve PGs.

Expressions of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in malignant peripheral nerve sheath tumor

BACKGROUND： Matrix metalloproteinase-9 （MMP-9） can degrade collagen IV （the main structural ingredient of basilar membrane）, and it also plays an important role in tumor vascularization, tumor cell progression, formation of metastatic focus, etc. Tissue inhibitor of metalloproteinase-1 （T1MP-1） can bind with MMP-9 to form 1 ： 1 compound and inhibit its activity, and can negatively regulate the tumor progression and metastasis. OBJECTIVE： To analyze the relationship of MMP-9 and T1MP-1 expressions with the pathological grade, metastasis and prognosis of malignant peripheral nerve sheath tumor （MPNST）. DESIGN： An observational comparative experiment. SETTING： Heze Medical College. PARTICIPANTS： Fifty-eight surgical pathological samples, which were clearly diagnosed to be MPNST, were collected from the pathological laboratory archives in the Department of Pathology, Heze Municipal Hospital from January 1988 to December 2003. The MPNST pathological types were common tumor in 53 cases, malignant triton tumor in 2 cases, epithelial MPNST in 2 cases and MPNST with gland differentiation in 1 case. The pathological grade was grade 1 in 11 cases, grade 2 in 24 cases and grade 3 in 23 cases. Besides, the resected tumor samples of 20 patients with benign peripheral nerve tumor （10 cases of nerve sheath tumor and 10 cases of neurofibromatosis） and the normal peripheral nerves （by-products of some surgeries） of 5 patients were also collected. The samples were used with the approval of the patients. Rat-anti-human MMP-9, TIMP-1 monoclonal antibody and S-P kit were purchased from Fuzhou Maixin Biotechnology, Co.,Ltd. METHODS： The documented paraffin blocks were again prepared to sections of 5 lJ m. The expressions of MMP-9 and TIMP-1 in the samples were detected with mmunohistochemical S-P method. The relationships of the MPNST severity, recurrence, metastasis and survival rate with the expressions of MMP-9 and TIMP-1 were analyzed. MAIN OUTCOME MEASURES： Relationships of MMP-9 and TIMP-1 expressions with the MPNST severity and prognosis. RESULTS： ①Expressions of MMP-9 and TIMP-1 in three tissues： MMP-9 and TIMP-1 stainings were mainly observed in cytoplasm. Among the 58 MPNST patients, the MMP-9 expression was significantly higher than those in normal peripheral nerve and benign tumor （P 〈 0.05）, while the TIMP-1 expression in MPNST was lower than those in normal peripheral nerve and benign tumor （P 〈 0.05）. ②Relationship of MMP-9 and TIMP-1 expressions with the severity and prognosis of MPNST： The expressions of both proteins were observed in the four subtypes. The positive expression of MMP-9 in the MPNST patients of grades 2 - 3 was significantly higher than that in the MPNST patients of grade 1 （P 〈 0.05）, while the expression of MMP-9 was significantly lower than that in the MPNST patients of grade 1 （P 〈 0.05）. The metastatic rate was positively correlated with MMP-9 expression （r =1.696, P 〈 0.05）, but negatively correlated with TIMP-1 expression （r = - 2.125, P 〈 0.05）. CONCLUSION： MMP-9 and TIMP-1 are associated with MPNST pathological grades and metastasis, and can be used as the indicators for judging the severity and orognosis of MPNST.

Effect of S-1 combined with oxaliplatin on serum tumor markers,matrix metalloproteinase and immune function in elderly patients with gastric cancer

Objective: To investigate the effect of Compound Tegafur and Oteracil Potassium Sustained Capsules (S-1) combined with oxaliplatin chemotherapy on serum tumor marker matrix metalloproteinase and immune function in elderly patients with gastric cancer. Methods:According to the random data table, 80 cases of elderly patients with gastric cancer were divided into control group and observation group (n=40), patients in the control group were treated with oxaliplatin combined with Capecitabine Tablets, and the observation group patients were treated with S-1 combined with oxaliplatin, all treated for 6 cycles, before and after treatment, levels of serum tumor markers, matrix metalloproteinase and immune function were compared between the two groups. Results: Before treatment, there was no significant difference in the levels of CEA, CA125, CA19-9, MMP-2, MMP-9, CD3+, CD4+, CD8+and CD4+/CD8+between the two groups;After treatment, the levels of CEA, CA125, CA19-9, MMP-2, MMP-9 and CD8+in the two groups were significantly lower than those in the same group before treatment, and the levels of the observation group[(7.79±2.78) ng/mL, (22.56±7.31) U/mL, (13.48±3.05) U/mL, (57.84±8.93) ng/mL, (199.14±67.39) ng/mL and (26.21±4.18)%] were significantly lower than those in the control group;Compared with the group before treatment, the levels of CD3+, CD4+and CD4+/CD8+in the two groups were significantly increased, and the observation group [(66.89±5.84)%, (41.63±5.24)% and (1.37±0.29)] was significantly higher than the control group. Conclusion: S-1 combined with oxaliplatin chemotherapy can effectively reduce serum tumor markers and matrix metalloproteinase levels, improve immune function, has an important clinical value.

突发性耳聋患者血清VCAM-1、ENA-78、MMP-2水平变化及检测意义

目的:探讨突发性耳聋患者血清血管细胞黏附分子-1(VCAM-1)、上皮中性粒细胞活化肽-78(ENA-78)、基质金属蛋白酶-2(MMP-2)水平变化及检测意义。方法:选取接受治疗的突发性耳聋患者136例为观察组,另选取同期体检健康者136例为对照组。采用ELISA法测定血清VCAM-1、ENA-78、MMP-2水平。根据听力损失程度将患者分为轻度组(46例)、中度组(51例)和重度组(39例)。根据治疗效果将患者分为疗效良好组(82例)和疗效不良组(54例)。比较观察组和对照组血清VCAM-1、ENA-78、MMP-2水平。比较不同听力损失程度及治疗效果患者血清VCAM-1、ENA-78、MMP-2水平。绘制受试者工作特征(ROC)曲线分析血清VCAM-1、ENA-78、MMP-2对突发性耳聋患者疗效不良的预测价值。结果:观察组血清VCAM-1、ENA-78、MMP-2水平高于对照组(均P<0.05)。与轻度组比较,中度和重度组血清VCAM-1、ENA-78、MMP-2水平逐渐升高(均P<0.05)。疗效良好组和疗效不良组患者临床资料比较差异无统计学意义(均P>0.05)。与疗效良好组比较,疗效不良组患者血清VCAM-1、ENA-78、MMP-2水平升高(均P<0.05)。血清VCAM-1、ENA-78、MMP-2三者联合预测突发性耳聋患者疗效不良的AUC高于血清单独指标预测的AUC(均P<0.05)。结论:突发性耳聋患者血清VCAM-1、ENA-78、MMP-2水平升高,与听力损失程度有关,三者联合对突发性耳聋患者治疗效果的预测价值较高。

电针对负透镜诱导型近视豚鼠视网膜中MMP-3和TIMP-3及Col3α1表达的影响

目的:探讨电针对负透镜诱导型近视豚鼠视网膜中基质金属蛋白酶(MMP)-3、金属蛋白酶组织抑制剂(TIMP)-3和III型胶原α1(Col3α1)表达的影响。方法:将80只豚鼠随机分为正常对照组、负透镜诱导型近视组、电针干预组和假穴组,每组20只。正常对照组不做任何干预,负透镜诱导型近视组、电针干预组和假穴组,右眼均配戴-6.0 D透镜,左眼不戴镜。戴镜同时电针干预组在合谷穴与太阳穴给予电针刺激,假穴组豚鼠在假穴位进行干预。造模前,造模2、4 wk检影验光检测屈光度,A超检测眼轴长度,HE染色观察视网膜组织结构变化,定量聚合酶链反应(Q-PCR)和蛋白免疫印迹(WB)检测视网膜中MMP-3、TIMP-3、Col3α1 mRNA和蛋白表达的情况。结果:造模2、4 wk,负透镜诱导型近视组与正常对照组相比眼轴长度均明显增加(均P<0.05),屈光度均明显降低(均P<0.05);与负透镜诱导型近视组相比,电针干预组干预后眼轴长度均减少(均P<0.05),屈光度均增加(均P<0.05)。HE染色显示,正常对照组豚鼠视网膜组织各层分界明显,排列规则;负透镜诱导型近视组视网膜厚度、内外核层厚度及细胞数量减少,排列不规则;电针干预组视网膜整体结构较为完善,排列较规则,组织各层形态结构未出现明显异常。Q-PCR和WB检测结果显示,负透镜诱导型近视组视网膜中MMP-3、TIMP-3和Col3α1 mRNA及蛋白表达均比正常对照组明显升高(均P<0.05);而电针干预组干预后视网膜中MMP-3、TIMP-3和Col3α1mRNA及蛋白表达均较负透镜诱导型近视组明显降低(均P<0.05)。结论:电针能够延缓负透镜诱导型近视豚鼠眼轴增长,下调负透镜诱导型近视豚鼠视网膜中的MMP-3、TIMP-3及Col3α1 mRNA及蛋白表达。

CTA联合血清MMP-9、TIMP-1在缺血性脑卒中诊断中的应用

目的 探究CT血管成像(CTA)联合血清基质金属蛋白酶9(MMP-9)、金属蛋白酶组织抑制因子1(TIMP-1)在缺血性脑卒中诊断中的应用。方法 选取2021年5月至2022年5月期间张家口市第一医院神经内科收治的140例脑卒中患者作为研究组研究对象,均行CTA检查,以数字血管造影(DSA)为金标准,分析CTA对缺血性脑卒中诊断价值,另选择同期至此院进行体检的健康者80名作为对照组,比较两组患者血清MMP-9、TIMP-1水平。结果 140例患者,共检查463条头颈血管,经CTA诊断无狭窄236条、轻度狭窄66条、中度狭窄36条、重度狭窄46条、闭塞22条,与DSA对照CTA诊断缺血性脑卒中患者血管狭窄程度的灵敏度为81.25%,特异度为90.15%;CTA诊断轻度狭窄患者74例、中度16例、重度46、闭塞4例,与DSA对照CTA诊断灵敏度82.50%、特异度83.33%;研究组患者血清MMP-9、TIMP-1表达水平均显著高于对照组患者,差异有统计学意义(t=73.668、33.925,P<0.05),且研究组患者随着狭窄程度增加,血清MMP-9、TIMP-1水平逐渐上升,差异有统计学意义(F=13298.37、901.001,P<0.05);MMP-9以247.14 ng/mL为临界值,阳性53例,阴性87例;TIMP-1均值(239.21 ng/mL)为临界值,阳性53例,阴性87例;以CTA阳性为基础,MMP-9、TIMP-1任一指标阳性则定义为联合诊断阳性,结果显示联合诊断灵敏度为88.75%,特异度为80.00%。结论 CTA联合血清MMP-9、TIMP-1对缺血性脑卒中诊断效能较高,临床应在密切观察缺血性脑卒中患者CTA检查基础上联合MMP-9、TIMP-1水平检测。

慢性牙髓炎患者龈沟液IL-6、MMP-8、TIMP-1水平及其与牙髓活力的关系

目的 检测慢性牙髓炎患者龈沟液白介素-6 (IL-6)、基质金属蛋白酶-8 (MMP-8)、基质金属蛋白酶抑制剂-1(TIMP-1)水平,并分析其与患者牙髓活力的关系。方法 选取106例慢性牙龈炎患者(观察组)和106例健康志愿者(对照组)。取龈沟液测定IL-6、MMP-8、TIMP-1水平,比较两组差异;比较观察组不同临床特征患者龈沟液IL-6、MMP-8、TIMP-1水平。牙髓活力电测仪测定牙髓活力,比较不同牙髓活力患者龈沟液IL-6、MMP-8、TIMP-1水平,Pearson法分析观察组牙髓电活力(EPT)值与龈沟液IL-6、MMP-8、TIMP-1水平的相关性。结果 观察组龈沟液IL-6、MMP-8均高于对照组[(61.28±8.11) ng/L vs.(38.15±7.04) ng/L、(33.04±6.02) ng/mL vs.(20.05±4.18) ng/mL](P<0.05),TIMP-1水平低于对照组[(1.35±0.30) ng/mL vs.(2.04±0.41) ng/mL](P<0.05);观察组病程≥12个月、合并糖尿病患者龈沟液IL-6、MMP-8水平均高于病程<12个月、未合并糖尿病患者(P<0.05),TIMP-1水平均低于病程<12个月、未合并糖尿病患者(P<0.05);中度、重度疼痛患者龈沟液IL-6、MMP-8水平均高于轻度疼痛(P<0.05),且重度疼痛均高于中度疼痛(P<0.05),而TIMP-1水平变化趋势正相反;牙髓活力下降、无活力患者龈沟液IL-6、MMP-8水平均高于活力正常(P<0.05),且牙髓无活力均高于活力下降(P<0.05),而TIMP-1水平变化趋势正相反;观察组患牙EPT与龈沟液IL-6、MMP-8水平均呈正相关(r=0.715、0.689, P<0.05),与TIMP-1水平呈负相关(r=-0.673, P<0.05)。结论 慢性牙龈炎患者龈沟液IL-6、MMP-8水平均升高,TIMP-1水平下降,且与病程、疼痛程度、合并糖尿病、牙髓活力均有关。

CTA联合血清MMP-9、TIMP-1对脑梗死患者颈动脉斑块诊断价值

目的探究计算机断层扫描血管成像(CTA)联合血清基质金属蛋白酶-9(MMP-9)、基质金属蛋白酶组织抑制剂-1(TIMP-1)对脑梗死患者颈动脉斑块诊断价值。方法选取2021年5月-2021年12月期间我院神经内科收治的140例脑梗死患者作为试验组研究对象,另选择同期至我院进行体检的健康者80例作为参照组。试验组患者均行CTA和数字减影血管造影(DSA),分析CTA诊断颈动脉斑块价值。试验组和参照组均接受血清MMF-9 TIMP-1检测。对比试验组与参照组的血清MMP-9、TIMP-1水平差异。在试验组中,以DSA为金标准,将患者分为斑块组和无斑块组,对比两组之间的血清MMP-9、TIMP-1水平差异,对CTA联合血清MMP-9、TIMP-1诊断颈动脉斑块的效果进行受试者特征曲线(ROC)分析。结果CTA检测结果显示存在颈动脉斑块者64例,无斑块组76例,CTA诊断颈动脉斑块敏感度为96.88%,特异性为97.37%,准确度为97.14%;试验组血清MMP-9水平显著高于参照组(P<0.05),TIMP-1水平显著低于参照组(P<0.05);斑块组血清MMP-9水平显著高于无斑块组(P<0.05),TIMP-1水平显著低于无斑块组(P<0.05);ROC曲线显示血清CTA、MMP-9、TIMP-1水平单独及联合诊断颈动脉斑块AUC值依次为0.979、0.835、0.812和0.993。结论CTA联合血清MMP-9、TIMP-1对脑梗死患者颈动脉斑块具有良好的诊断价值。